GU Cancers 2022 | Next steps for combination immunotherapies for RCC

Name: Next steps for combination immunotherapies for RCC
Uploaded: 2022-02-23T00:00:00Z
Duration: 58 s
Description: Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the future of combination immunotherapies for patients with renal cell carcinoma, and talks on some of the key unmet needs and research gaps in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Matthew R. Zibelman • 23 Feb 2022

GU Cancers 2022

Genitourinary Cancer Kidney Cancer Antibodies Axitinib Nivolumab

Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the future of combination immunotherapies for patients with renal cell carcinoma, and talks on some of the key unmet needs and research gaps in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.